Asset Details
Do you wish to reserve the book?
Bruton’s tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bruton’s tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn
Do you wish to request the book?
Bruton’s tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bruton’s tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn
2025
Overview
The first of several phase 3 trials examining efficacy in relapsing MS has not been able to demonstrate a significant benefit and has also raised important safety concerns. More results are on their way and it will be important to understand whether the safety signals identified are drug- or class-specific and whether other BTKi also fail to reach their endpoints for relapsing MS. However, as reported in preliminary data for another BTKi, it may be that they will have more of a role in progressive disease as hinted by the unraveling of relevant molecular mechanisms and pathways.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
